Healing · 5mg × 10 vials
it tells the body to build new blood supply into broken tissue, which is why nearly every connective tissue, gut lining, and vascular injury model in rats responds to it.
BPC-157 is a 15-amino-acid pentadecapeptide derived from a protective sequence in human gastric juice (hence "Body Protection Compound"). Its primary documented mechanism is angiogenic, it upregulates VEGFR2 (vascular endothelial growth factor receptor 2) and drives new capillary formation into damaged tissue, which is why every animal model with a healing endpoint (tendon transection, ligament tear, gut ulcer, anastomosis, bone defect) shows accelerated repair. Secondary mechanisms include modulation of the nitric oxide (NO) system (BPC-157 interacts with both the NO-synthase and the NO-pathway counter-regulation, which is how it manages to both protect against ischemia and protect against the rebound damage from reperfusion), upregulation of growth hormone receptor expression in fibroblasts (which is the proposed mechanism for tendon healing synergy with the GH axis), and stabilization of the dopamine and serotonin systems in stress-injury models. The gut effects (the original research target, since the peptide came out of gastric juice) appear mediated through enteric vasculature recovery plus restoration of tight junction integrity. In plain language: it tells the body to build new blood supply into broken tissue, which is why nearly every connective tissue, gut lining, and vascular injury model in rats responds to it.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This is the bread-and-butter dose for general healing, gut tolerance during a GLP-1 cycle, low-level inflammation, or maintenance recovery. 5 mg vial reconstituted with 2 ml BAC = 2.5 mg/ml, 250 mcg = 0.10 ml = 10 IU on a U-100 syringe. One 5 mg vial lasts 20 days at this dose, a 10-vial kit covers ~200 days of continuous use, well past a full cycle.
Standard working dose for active soft tissue injury (tendinitis, ligament strain, muscle tear), chronic gut issues (IBD-adjacent, GERD), or to manage GI sides from GLP-1 titration. Split dosing is preferred for acute injury because of the short half-life, AM + PM keeps blood levels steadier. 10 mg vial reconstituted with 2 ml BAC = 5 mg/ml, 500 mcg = 0.10 ml = 10 IU. One 10 mg vial lasts 20 days at 500 mcg/day.
Aggressive protocol for stubborn or chronic injuries (rotator cuff, Achilles, golfer's/tennis elbow, plantar fasciitis, post-surgical recovery). Local injection (subQ into the skin closest to the damaged tissue) is the community-favored route, the rationale is that BPC-157 drives angiogenesis at the injection site itself, so concentrating it where you want new capillaries makes sense even though it works systemically too. Almost always paired with TB-500 (Wolverine blend) at this level.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
foundational review of mechanism + animal evidence across 20+ years of work
Read study ↗PubMedHsieh et al, J Orthop Res 2017 - "BPC 157 promotes tendon healing"Achilles tendon transection model, accelerated tenocyte proliferation
Read study ↗PubMedChang et al, J Appl Physiol 2011 - "BPC 157 enhanced tendon healing through VEGFR2"defines the VEGFR2 mechanism that explains the angiogenic effect
Read study ↗PubMedSeiwerth et al, Curr Pharm Des 2014 - BPC 157 and standard angiogenic growth factorsclarifies the VEGF/angiogenesis pathway interaction
Read study ↗PubMedSikiric et al, J Physiol Pharmacol 2010 - Stable gastric pentadecapeptide BPC 157 in gut healinggut/ulcer/IBD-relevant data
Read study ↗PubMedVukojevic et al, Eur J Pharmacol 2018 - BPC 157 and NO systemNO pathway modulation
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Injection site irritation: most-reported side effect, mild redness or tenderness for a few hours post-injection. Resolves on its own. Rotating sites minimizes it.
Mild fatigue or "feeling off" first week: small subset of users report this in the first 3-7 days, attributed to the body diverting resources into the repair response. Resolves by week 2.
Mild GI changes: a few users report transient loose stool or appetite shifts in the first week, especially at higher doses (500 mcg+ daily). Generally resolves.
Headache: rare, isolated reports, no consistent pattern.
Subjective body temperature awareness: some users report feeling slightly warm or flushed for an hour or so post-injection, particularly at higher doses. No safety signal, just a sensation.
The dominant community report is "felt nothing acutely, noticed I was healing faster a few weeks in", which matches the angiogenic mechanism (slow tissue-level effects, not an acute drug feel).
Route: SubQ (most common), localized injection near injury site (community standard), IM tolerated, oral (controversial)
Injection site: SubQ abdomen, outer thigh, or love handle for systemic effect. Local injection near the injury site (closest skin to the affected tendon/joint) is the community-favored route for soft tissue injury.
Storage: Refrigerated, 4-6 weeks once reconstituted. Lyophilized vials stable at room temp shipping; refrigerate on arrival.
Notes: BPC-157 is unusually stable, it survives the GI tract better than most peptides (which is what fueled the oral debate), but injection beats oral for bioavailability by a wide margin. Half-life is short (~4 hr plasma), which is why daily or twice-daily dosing is the convention. No food timing requirements. Some users split a daily dose AM/PM for steadier blood levels during acute injury phases.